Everything below concerns Reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
== Veterinary use == Apomorphine is used to inducing vomiting in dogs after ingestion of various toxins or foreign bodies. It can be given subcutaneously, intramuscularly, intravenously, or, when a tablet is crushed, in the conjunctiva of the eye. The oral route is ineffective, as apomorphine cannot cross the blood–brain barrier fast enough, and blood levels don't reach a high enough concentration to stimulate the chemoreceptor trigger zone. It can remove around 40–60% of the contents in the stomach. One of the reasons apomorphine is a preferred drug is its reversibility: in cases of prolonged vomiting, the apomorphine can be reversed with dopamine antagonists like the phenothiazines (for example, acepromazine). Giving apomorphine after giving acepromazine, however, will no longer stimulate vomiting, because apomorphine's target receptors are already occupied. Apomorphine does not work in cats, who have too few dopamine receptors.
=== Direct air capture === Anion exchange resins readily absorb CO2 when dry and release it again when exposed to moisture. This makes them one of the most promising materials for direct carbon capture from ambient air or direct air capture, as the moisture swing works to replace the more energy-intensive temperature swing or pressure swing used with other sorbents which then facilitates the desired outcome. A prototype demonstrating this process has been developed by Klaus Lackner at the Center for Negative Carbon Emissions.
=== Disability and death === Due to distance, Hodgkin decided not to attend the 1987 Congress of the International Union of Crystallography in Australia. However, despite increasing frailty, she astounded close friends and family by going to Beijing for the 1993 Congress, where she was welcomed by all. She died in July 1994 after a stroke, at her husband's home in the village of Ilmington, near Shipston-on-Stour, Warwickshire.
=== Environmental triggers === Environmental factors, such as glandular viral infection, could prompt epithelial cells to activate the HLA-independent innate immune system through toll-like receptors. Although several infectious, exogenous agents have been implicated in the pathogenesis of Sjögren's disease, such as Epstein-Barr virus (EBV), human T-lymphotropic virus 1, and hepatitis C virus, their association with Sjögren's disease appears weak. While EBV is present in the salivary glands of normal individuals, a high incidence of EBV reactivation in Sjögren's patients has been reported with increased levels of EBV DNA. This indicates viral reactivation and the inability of lymphoid infiltrates to control EBV replication in Sjögren's disease, leading to the initiation or perpetuation of an immune response in target organs. Nonetheless, exactly how EBV reactivation is induced in lesions of patients with Sjögren's disease, and which specific molecular mechanisms are involved in the process of viral reactivation, remain to be clarified.
Sources: en.wikipedia.org
== The Future Possibilities of Venomics == The field of venomics has been vastly revamped since its origin in the 20th century and continues to be improved with contemporary methods such as next generation sequencing and nuclear magnetic resonance spectroscopy. From this trend, it would seem that venomics will be progressively enhanced in its capabilities through the persistent technological advancements of the 21st century. As previously mentioned, a potential route that can be expanded upon further by venomics could be venom-specific molecules being co-opted into specialised medicines. The first example of this was in the early 1970s, when Captopril was found to be an inhibitor of angiotensin converting enzymes (ACE) and had the means of treating hypertension in people. Glenn King discusses the current state of venom-derived drugs, with six drugs derived from venom being FDA-approved and ten more currently being under clinical trials. Michael Pennington gives a detailed update on the current landscape of venom-derived drugs and the potential future of the field (Table 1). Anti-venoms is another branch of medicine, which needs to be improved due to the problems many developing countries face with venomous animals. Places like south/southeast Asia and sub-Saharan Africa are where many cases of both morbidity (limb amputation) and mortality take place.
Hitler, aiming to use the crisis as a pretext for war, now demanded not only the annexation of the Sudetenland but also the immediate military occupation of Bohemia, Moravia and Slovakia, thus giving the Czechoslovak army no time to adapt its defence measures to the new borders. Hitler, in a speech at the Sportpalast in Berlin, claimed that the Sudetenland was "the last territorial demand I have to make in Europe" and gave Czechoslovakia a deadline of 28 September 1938 at 2:00 p.m. to cede the Sudetenland to Germany or face war. To achieve a solution, the Italian dictator, Benito Mussolini, suggested a conference of the major powers in Munich, and on 29 September, Hitler, Daladier and Chamberlain met and agreed to Mussolini's proposal (actually prepared by Hermann Göring) and signed the Munich Agreement. They accepted the immediate occupation of the Sudetenland. The Czechoslovak government, though not party to the talks, submitted to compulsion and promised to abide by the agreement on 30 September. The Sudetenland was assigned to Germany between 1 and 10 October 1938. The Czech part of Czechoslovakia was subsequently invaded by Germany in March 1939, with a portion being annexed and the remainder turned into the Protectorate of Bohemia and Moravia. The Slovak part declared its independence from Czechoslovakia and became the Slovak Republic (Slovak State), a satellite state allied to Germany.
The town of Billericay was established in the 13th century in the Manor and Parish of Great Burstead. The Manor of Burgestede is first recorded in an Anglo-Saxon will of 975 AD. In the Domesday Book of 1086, two separate manors are recorded as Burghestada. The name Great Burstead is first recorded in the early 13th century, but the division into Great and Little Burstead Manors had happened by the time of the Norman Conquest. The town of Billericay, first recorded as Byllyrica in 1291, is understood to have been founded in the 13th century by the Abbot of West Ham, head of the Cistercian community of Stratford Langthorne Abbey, 20 miles (32.2 km) away on the Lower Lea, in what is now inner London. The Abbey held the Manor of Great Burstead at the time. The town was established at the High Street. Like the abandoned Roman settlement just to the south, it benefitted from a prominent position on the high ground forming the watershed on the catchment areas of the rivers Crouch and Wid. It was also on the crossroads (at Sun Corner) of the road from the Thames to Chelmsford (the modern B1007) and the A129 road linking Hutton to Wickford; it is believed that the Crouch may have been navigable as far as Wickford at that time. At this time, the parish church for Billericay was at St Mary Magdalene, Great Burstead. By the 14th century, a chantry chapel had been built on the High Street, which became a chapel of ease to Great Burstead following the Reformation; it eventually became a parish church in 1844, also dedicated to St Mary Magdalen.
Sources: en.wikipedia.org
In radiology, various X-ray views use terminology based on where the X-ray beam enters and leaves the body, including the front to back view (anteroposterior), the back to front view (posteroanterior), and the side view (lateral).
=== Sterilization of biomedical materials === Supercritical CO2 is an alternative for thermal sterilization of biological materials and medical devices with combination of the additive peracetic acid (PAA). Supercritical CO2 does not sterilize the media, because it does not kill the spores of microorganisms. Moreover, this process is gentle, as the morphology, ultrastructure and protein profiles of inactivated microbes are preserved.
Xi Jinping was born on 15 June 1953 in Beijing as the third child of Xi Zhongxun and his second wife Qi Xin. A Chinese Communist Party (CCP) revolutionary, Xi's father held a series of posts after the founding of the People's Republic of China in 1949, including head of the Party Publicity Department, vice premier, and vice chairperson of the Standing Committee of the National People's Congress. Xi has two older sisters, Qi Qiaoqiao, born in 1949, and Qi An'an (齐安安), born in 1952. Xi's father was from Fuping County, Shaanxi. Xi went to Beijing Bayi School, where students were primarily the children of high-ranking military officials. In 1963, when Xi was ten years old, his father was purged from the CCP and sent to work in a factory in Luoyang, Henan. Following the start of the Cultural Revolution in 1966, Xi was persecuted due to his father's status. Student militants ransacked the Xi family home. His mother was forced to publicly denounce his father, as he was paraded before a crowd as an enemy of the revolution. After the Bayi School closed down in 1967, Xi was transferred to the Beijing No. 25 School. In 1968, when Xi was aged 15, his father was imprisoned. Xi left Beijing and arrived in Liangjiahe Village, Yan'an, Shaanxi in the Down to the Countryside Movement. At the time, Yan'an was one of the poorest places in the country. After a few months, unable to stand rural life, he ran away to Beijing. He was arrested during a crackdown on deserters from the countryside and sent to a work camp to dig ditches.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.